Delving into the Latest Updates on Qingdao Yongzhan Medical Technology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

主要目的：评估在带状疱疹后神经痛（PHN）患者中FM888胶囊的安全性、耐受性。 FM888胶囊治疗PHN患者有效性的概念性验证。次要目的：评估经FM888胶囊治疗PHN患者对其睡眠、临床总体印象的影响。了解FM888胶囊在PHN患者中的药代动力学特征。

[Translation]

Primary objectives: To evaluate the safety and tolerability of FM888 capsules in patients with postherpetic neuralgia (PHN). To provide proof of concept for the effectiveness of FM888 capsules in treating PHN patients. Secondary objectives: To evaluate the effects of FM888 capsules on sleep and clinical global impression in PHN patients. To understand the pharmacokinetic characteristics of FM888 capsules in PHN patients.

Start Date-

Sponsor / Collaborator

Qingdao Yongzhan Medical Technology Co., Ltd.

CTR20211497 / CompletedPhase 1

评估口服FM888胶囊在中国健康成年受试者中单中心、随机、双盲、安慰剂对照、单次及多次给药、剂量递增的安全性、耐受性、药代动力学特征和食物对药代动力学影响的I期临床研究

[Translation] A single-center, randomized, double-blind, placebo-controlled, single- and multiple-dose, dose-escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and food effects of oral FM888 capsules in healthy Chinese adult subjects

主要目的评估健康成人空腹单次和多次口服FM888胶囊后的安全性、耐受性。次要目的评估健康成人空腹单次和多次口服FM888胶囊后的药代动力学特征。评估食物对健康成人口服FM888胶囊后的药代动力学特征的影响。健康成人空腹单次口服FM888胶囊600mg后的代谢产物分析及鉴定。

[Translation]

Primary objective To evaluate the safety and tolerability of FM888 capsules after single and multiple oral administration in healthy adults on an empty stomach. Secondary objective To evaluate the pharmacokinetic characteristics of FM888 capsules after single and multiple oral administration in healthy adults on an empty stomach. To evaluate the effect of food on the pharmacokinetic characteristics of FM888 capsules after oral administration in healthy adults. To analyze and identify the metabolites of FM888 capsules 600 mg after a single oral administration in healthy adults on an empty stomach.

Start Date08 Sep 2021

Sponsor / Collaborator

Qingdao Yongzhan Medical Technology Co., Ltd.

100 Clinical Results associated with Qingdao Yongzhan Medical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Qingdao Yongzhan Medical Technology Co., Ltd.

Login to view more data

100 Deals associated with Qingdao Yongzhan Medical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Qingdao Yongzhan Medical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data